An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

NCT03334695 | Completed Phase 2 Results FDA Drug

• 3 other identifiers: CR1083982017-003194-33VAC18193RSV2002
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess a trend for the prophylactic efficacy of a single dose of 1\*10\^11 virus particles (vp) of adenovirus serotype 26 respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) administered intramuscularly to adults aged 18-50 years in the respiratory syncytial virus (RSV) challenge model in terms of reduction of nasal wash viral load compared to placebo.

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Area Under the Viral Load-Time Curve (VL-AUC) of Respiratory Syncytial Virus (RSV) by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR)

  VL-AUC for RSV was determined by qRT-PCR assay of nasal wash samples. Here, values below the lower limit of quantification (LLOQ) were imputed with zero.

  From Day 2 to Day 12

Secondary Outcomes (13)

• Peak Viral Load of RSV-A Memphis 37b

  From Day 2 to Day 12

• Viral Load by Quantitative RT-PCR Assay on Day 6 and 7

  Day 6 (0 hour and 12 hours) and Day 7 (0 hour and 12 hours)

• VL-AUC of RSV by Quantitative Culture of RSV (Plaque Assay) on Day 6 and 7

  Day 6 (0 hour and 12 hours) and Day 7 (0 hour and 12 hours)

• Percentage of Participants With Symptomatic RSV Infections

  From Day 2 to Day 12

• Total Clinical Symptoms Score at Day 6 and 7

  Day 6 and 7: morning, afternoon and evening

Study Arms (2)

Group 1: Ad26.RSV.preF

EXPERIMENTAL

Participants will receive single intramuscular injection of 1\*10\^11 virus particles (vp) of Ad26.RSV.preF during Day -90 to Day -28. On Day 0, intranasal challenge with respiratory syncytial virus (RSV)-A Memphis 37b virus will occur for all participants.

Biological: Ad26.RSV.preF

Group 2: Placebo

PLACEBO COMPARATOR

Participants will receive single intramuscular injection of placebo as sterile 0.9 percent (%) saline for injection during Day -90 to Day -28. On Day 0, intranasal challenge with RSV-A Memphis 37b virus will occur for all participants.

Drug: Placebo

Interventions

Ad26.RSV.preF BIOLOGICAL

Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1\*10\^11 vp in single-use vials.

Also known as: JNJ-64400141

Group 1: Ad26.RSV.preF

Placebo DRUG

Placebo will be administered as sterile 0.9% saline for injection.

Group 2: Placebo

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Each participant must sign an Informed Consent Form (ICF) indicating that he or she understands the purpose of and procedures required for the study, is willing to participate in the study and attend all scheduled visits, is willing to be isolated and stay in the clinic for the quarantine phase, and is willing and able to comply with all study procedures and adhere to the prohibitions and restrictions specified in this protocol
• Participants must be in good health, without significant medical illness, on the basis of a medical evaluation that reveals the absence of any clinically relevant abnormality and includes a physical examination (including height and weight), skin examination, medical history, vital signs (systolic and diastolic blood pressure and heart rate, respiratory rate, and body temperature), and the results of clinical laboratory tests performed within 56 days of vaccination. If there are abnormalities, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the participant's source documents and initialed by the investigator
• Participants must have a non-clinically significant 12-lead electrocardiogram (ECG) within 56 days of vaccination including: normal sinus rhythm (heart rate between 50 and 100 beats per minute \[bpm\], extremes included); QT interval corrected for heart rate according to Fridericia (QTcF) interval less than or equal to (\<=) 450 millisecond (ms); QT interval corrected for heart rate according to Bazett (QTcB) interval \<= 450 ms; QRS interval less than (\<) 120 ms; PR interval \<= 210 ms
• Participants must be sero-suitable for respiratory syncytial virus (RSV) within 90 days of vaccination (low immunity to the RSV-A Memphis 37b virus using a virus neutralization assay
• Participant must be healthy on the basis of clinical laboratory tests performed within 56 days of vaccination. If the results of the laboratory screening tests are outside the local laboratory normal reference ranges and additionally within the limits of toxicity Grade 1 according to the US Food and Drug Administration (FDA) toxicity tables (that is, for tests in the FDA table), the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator

You may not qualify if:

• Participant has acute illness (this does not include minor illnesses such as diarrhea) or temperature greater than or equal to (\>=) 37.8 degree Centigrade within 24 hours prior to study vaccination
• Participant has history of malignancy (exceptions are basal cell carcinomas of the skin treated over 5 years prior to vaccination considered cured with minimal risk of recurrence)
• Participant has chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and hepatitis C antibody, respectively
• Participants having donated or lost more than 1 unit of blood (470 milliliter \[mL\]) within 60 days or more than one unit of plasma within 7 days
• Participants with active acute respiratory infection

Sponsors & Collaborators

• Janssen Vaccines & Prevention B.V.: lead

Study Sites (1)

hVIVO Services Limited

London, E1 2AX, United Kingdom

Location

Limitations and Caveats

As no respiratory syncytial virus (RSV) vaccine has been previously tested in a human challenge model, the relationship between the results from this human challenge model and vaccine efficacy against natural infection is unknown.

Results Point of Contact

• Title: Medical Leader
• Organization: Janssen Research & Development, LLC

ClinicalTrialDisclosure@its.jnj.com

844-434-4210

Study Officials

• Janssen Vaccines & Prevention B.V. Clinical Trial

  Janssen Vaccines & Prevention B.V.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 16, 2017
• First Posted: November 7, 2017
• Study Start: October 16, 2017
• Primary Completion: July 10, 2018
• Study Completion: November 27, 2018
• Last Updated: February 4, 2025
• Results First Posted: July 23, 2021

Record last verified: 2025-01

Locations

GB (1)